Coronavirus disease-2019 (COVID-19) has affected more than 200 countries worldwide. This disease has hugely affected healthcare systems as well as the economy to an extent never seen before. To date, COVID-19 infection has led to about 165000 deaths in 150 countries. At present, there is no specific drug or efficient treatment for this disease. In this analysis based on evidential relationships of the biological characteristics of MSCs, especially umbilical cord (UC)-derived MSCs as well as the first clinical trial using MSCs for COVID-19 treatment, we discuss the use of UC-MSCs to improve the symptoms of COVID-19 in patients.

中文翻译：

---

来自人脐带组织的现成的间充质干细胞可以显着改善COVID-19患者的症状：证据关系分析。

2019年冠状病毒病（COVID-19）已影响全球200多个国家。这种疾病以前所未有的程度极大地影响了医疗系统和经济。迄今为止，COVID-19感染已在150个国家/地区导致约165,000例死亡。目前，尚无针对该疾病的特异性药物或有效治疗方法。在此分析中，基于MSC的生物学特性的证据关系，尤其是脐带（UC）来源的MSC以及使用MSC进行COVID-19治疗的首项临床试验，我们讨论了使用UC-MSC改善症状的方法患者中COVID-19的含量。